Novavax/King Estrasorb approval
Executive Summary
Novavax and King will launch topical estrogen emulsion Estrasorb in early 2004 via 125 sales reps, following FDA approval Oct. 9. Hormone therapy approved for vasomotor symptoms; carries class warning from Women's Health Initiative study. Former Lilly exec Ford Lynch tapped to head sales and marketing efforts. NDA was submitted in June 2001 but was withdrawn and resubmitted Sept. 9, 2002. FDA later extended the review time by three months (1"The Pink Sheet" June 30, 2003, In Brief)...